Any semax vs selank comparison starts from a shared origin: both come out of the same Russian institute and both use the same route of administration. They act on different systems, though. Semax works on BDNF and dopaminergic systems, oriented toward activation and attention; Selank works on GABAergic and serotonergic systems, oriented toward reducing anxiety.
The shared origin
Both come from the same line of Soviet and later Russian research on regulatory peptides: short molecules derived from larger proteins, modified to resist degradation and retain activity on the central nervous system.
They also share:
- Origin as a fragment of a larger molecule: ACTH in the case of Semax, tuftsin in the case of Selank.
- Modification with proline and glycine to increase stability.
- The intranasal route as the usual form of administration.
- Registration as a medicine in Russia, with no approval in other frameworks.
What they do not share is the mechanism, and therefore not the intended effect either.
Comparison table
| Semax | Selank | |
|---|---|---|
| Molecule of origin | ACTH fragment | Tuftsin |
| Systems involved | BDNF, dopaminergic | GABAergic, serotonergic |
| Direction of effect | Activation, attention | Reduced anxiety |
| Effect on activity | Tends to increase it | Tends to reduce reactivity |
| Study context in Russia | Cognitive impairment and cerebral circulatory disorders | Anxiety disorders |
| Sedation described | No | Described as minimal |
| Western evidence | None under FDA/EMA standards | None under FDA/EMA standards |
When each one is studied
Within the Russian registration, their indications do not overlap:
Semax has been studied in settings where the goal is to sustain or recover cognitive and attentional function.
Selank has been studied in anxiety settings, where the goal is to reduce reactivity.
These are opposite directions along the same axis. They are not interchangeable, and reading semax vs selank as "two nootropics" loses exactly what separates them.
The details of each are in the article on Semax and the one on Selank.
The combination: what supports the hypothesis, and what evidence does not
The combination of the two circulates, with an argument worth examining.
The hypothesis: they act on different systems and in complementary directions (cognitive activation without the anxious reactivity that sometimes comes with it). Since they do not compete for the same receptor, interference would be unlikely.
What is missing: no published study evaluates the combination. Not preclinical, not clinical. The same reasoning applies here as with the BPC-157 and TB-500 combination: a coherent mechanistic hypothesis is not a finding, and a combination can behave differently from the sum of its parts.
Without a three-arm design (A alone, B alone, A+B), there is no way to know whether the effect is additive, synergistic, null, or interfering.
Differences in tolerability profile
Both are described with favorable profiles in Russian clinical use, with infrequent adverse effects, largely related to local irritation from the intranasal route.
The differences described:
Semax, given its activating orientation, has been associated with disturbed sleep when it is administered in the second half of the day.
Selank, despite being described as minimally sedating, acts on the GABAergic system, which makes caution reasonable regarding interactions with other substances that act on that system.
Neither observation comes from tolerability studies accessible for outside evaluation.
What the evidence does not settle
For both, and for the combination:
- Efficacy under Western standards: no trials that meet them.
- Human pharmacokinetics by the intranasal route: not quantified in accessible literature.
- Prolonged use and tolerance: no data.
- The combination: no studies at all.
The frame is the same one that applies to this whole cluster: promising research, not proven under the standards treated here as the reference.
Frequently asked questions
Which one is better?
The semax vs selank question has no answer as posed, because the two are not after the same thing. Semax points toward activation and attention; Selank, toward reduced anxiety. Those are different directions.
Can they be used together?
That practice circulates, and its rationale is mechanistic: they act on different systems and do not compete for the same receptor. There is no study of the combination.
Is either one approved outside Russia?
Neither. Both are registered in Russia for certain indications and lack approval from the FDA, EMA, and INVIMA.
Why are they given through the nose?
Because the intranasal route offers access to the central nervous system while partly bypassing the blood-brain barrier. It is the usual route in Russian use of both compounds.
References
- Dolotov OV, et al. Semax, an analogue of ACTH(4-7), regulates expression of immediate early genes and BDNF in rat hippocampus. Journal of Neurochemistry, 2006;97(Suppl 1):82–86. DOI: 10.1111/j.1471-4159.2006.03658.x
- Volkova A, et al. Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission. Frontiers in Pharmacology, 2016;7:31. DOI: 10.3389/fphar.2016.00031
- Zozulya AA, et al. The inhibitory effect of Selank on enkephalin-degrading enzymes. Bulletin of Experimental Biology and Medicine, 2001;131(4):315–317. DOI: 10.1023/A:1017979514274
- Lochhead JJ, Thorne RG. Intranasal delivery of biologics to the central nervous system. Advanced Drug Delivery Reviews, 2012;64(7):614–628. DOI: 10.1016/j.addr.2011.11.002
Written by the Bionic Editorial Team. Last reviewed: August 2026.
How we work: our editorial policy and source hierarchy.
This content is strictly educational and does not constitute medical advice, diagnosis or a therapeutic recommendation. The compounds mentioned are research products (Research Use Only) and are not approved by INVIMA, FDA, EMA or ANSM for therapeutic use in humans. Any health-related decision should be made with a licensed medical professional.